P-1690. Evaluation of an Ultrasensitive Urine LAM Assay for Tuberculosis Using Optofluidic Single-Molecule Counting Technology

Abstract Background Sputum-based diagnostics for tuberculosis (TB) are limited in sensitivity, accessibility, and applicability—particularly in children, people living with HIV (PLHIV), and patients with extrapulmonary TB. Urine lipoarabinomannan (LAM) is a well-established TB biomarker, but existing tests are restricted to PLHIV and offer limited sensitivity (LoD ∼250 pg/mL). Fluxus’ single-molecule counting platform integrates optics and microfluidics to enable ultrasensitive detection of proteins in clinical samples. We present preliminary analytical and clinical performance data for a prototype urine LAM assay developed using this platform. Methods Analytical characterization included determination of limits of detection (LoD) and quantification (LoQ), dilution linearity, spike recovery, intra- and inter-assay precision, and crossreactivity. Preliminary clinical performance will be evaluated on biobanked urine samples from a cohort of adults with suspected TB, and LAM concentrations will be compared to a TB microbiologic reference standard. Results The assay demonstrated LoD and LoQ of 0.068 and ∼2 pg/mL, respectively, with a >5-log dynamic range. Spike recovery in urine averaged 106% (range 80%–130%) and dilution linearity was maintained across 0.01–100 ng/mL (mean 102%, range 86%–134%). Intraassay CV averaged 7.4%, and interassay CV was < 15% across the quantifiable range. No crossreactivity was observed with Mycobacterium smegmatis LAM. Testing in clinical samples is ongoing. Conclusion The Fluxus ultrasensitive LAM assay offers sub-pg/mL sensitivity, strong linearity, and reproducibility, enabling accurate quantification of LAM in urine across a broad range. Clinical testing in a diverse cohort is ongoing. There is a potential for Fluxus’ single-molecule counting technology to transform non-sputum-based TB diagnostics and support broader use of LAM testing. Disclosures Cathy Le, BS, Fluxus: Employee Tiffany Truong, MS, Fluxus: Employee Justin Nguyen, BS, Fluxus: Employee|Fluxus: Employee Niamh Nolan, MS, Fluxus: Advisor/Consultant|Fluxus: Advisor/Consultant Renee Tobias, MS, Fluxus: Employee Frank Zaugg, PhD, Fluxus: Employee Peter Wagner, PhD, Fluxus: Employee Valerie Brachet, PhD, Fluxus: Employee Johanna Sandlund, MD, PhD, Fluxus: Employee

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2026-01-01
DOI
https://doi.org/10.1093/ofid/ofaf695.1864
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-1690. Evaluation of an Ultrasensitive Urine LAM Assay for Tuberculosis Using Optofluidic Single-Molecule Counting Technology

Niamh Nolan, Renee Tobias, Johanna Sandlund, Valérie Brachet et al.
Open Forum Infectious Diseases
Tuberculosis Research and Epidemiology
article

P-1690. Evaluation of an Ultrasensitive Urine LAM Assay for Tuberculosis Using Optofluidic Single-Molecule Counting Technology

Niamh Nolan, Renee Tobias, Johanna Sandlund, Valérie Brachet, Frank Zaugg, Peter Wagner, Justin Ke Nguyen, Tiffany Truong, Harisha Ramachandraiah, Cathy Le
article en

Abstract

Abstract Background Sputum-based diagnostics for tuberculosis (TB) are limited in sensitivity, accessibility, and applicability—particularly in children, people living with HIV (PLHIV), and patients with extrapulmonary TB. Urine lipoarabinomannan (LAM) is a well-established TB biomarker, but existing tests are restricted to PLHIV and offer limited sensitivity (LoD ∼250 pg/mL). Fluxus’ single-molecule counting platform integrates optics and microfluidics to enable ultrasensitive detection of proteins in clinical samples. We present preliminary analytical and clinical performance data for a prototype urine LAM assay developed using this platform. Methods Analytical characterization included determination of limits of detection (LoD) and quantification (LoQ), dilution linearity, spike recovery, intra- and inter-assay precision, and crossreactivity. Preliminary clinical performance will be evaluated on biobanked urine samples from a cohort of adults with suspected TB, and LAM concentrations will be compared to a TB microbiologic reference standard. Results The assay demonstrated LoD and LoQ of 0.068 and ∼2 pg/mL, respectively, with a >5-log dynamic range. Spike recovery in urine averaged 106% (range 80%–130%) and dilution linearity was maintained across 0.01–100 ng/mL (mean 102%, range 86%–134%). Intraassay CV averaged 7.4%, and interassay CV was < 15% across the quantifiable range. No crossreactivity was observed with Mycobacterium smegmatis LAM. Testing in clinical samples is ongoing. Conclusion The Fluxus ultrasensitive LAM assay offers sub-pg/mL sensitivity, strong linearity, and reproducibility, enabling accurate quantification of LAM in urine across a broad range. Clinical testing in a diverse cohort is ongoing. There is a potential for Fluxus’ single-molecule counting technology to transform non-sputum-based TB diagnostics and support broader use of LAM testing. Disclosures Cathy Le, BS, Fluxus: Employee Tiffany Truong, MS, Fluxus: Employee Justin Nguyen, BS, Fluxus: Employee|Fluxus: Employee Niamh Nolan, MS, Fluxus: Advisor/Consultant|Fluxus: Advisor/Consultant Renee Tobias, MS, Fluxus: Employee Frank Zaugg, PhD, Fluxus: Employee Peter Wagner, PhD, Fluxus: Employee Valerie Brachet, PhD, Fluxus: Employee Johanna Sandlund, MD, PhD, Fluxus: Employee

Open Forum Infectious DiseasesVol. 13(Supplement_1)
FIND (CH), Fluxion Biosciences (United States) (US)
Good health and well-being
Openalex Percentile: Top 90%
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.